London, July 6, 2026, 16:11 BST
- Frontier IP (LON:FIPP) last showed at 15.5p/16.5p. Shares gained 17.86%, with 1.47 million trading hands, AJ Bell data said.
- Frontier owns 32.9% of InSignals Neurotech, which landed a €317,762 PT2030 grant. The company wants to build a Parkinson’s app.
- The only analyst tracked by Investors Chronicle/LSEG is sticking with a 41p target for the next 12 months. Frontier’s shareholders vote July 15 on the second piece of its June share offer.
Frontier IP Group Plc (LON:FIPP) climbed Monday after a small health-tech grant brought fresh focus to the gap between the firm’s market cap and its book value. Hargreaves Lansdown gave a delayed quote of 15.5p to sell and 16.5p to buy, 2p higher, with the stock opening at 14p. The London Stock Exchange ran its usual 0800 to 1630 BST session.
The stock outpaced the junior market. The FTSE AIM All-Share (INDEXFTSE:AXX) added 0.17% to 777.38 at 15:27 BST, Fidelity data showed.
Frontier said its portfolio company InSignals Neurotech secured a €317,762 grant, funded in part by the European Union under Portugal 2030 and the NORTE 2030 program. InSignals plans to use the grant to expand its algorithms for use on other wearable devices, like smartwatches and rings, and is rolling out a mobile app aimed at Parkinson’s patients and their caregivers.
CEO Neil Crabb said InSignals’ tech could “optimise the diagnosis and treatment” of Parkinson’s along with other neurological conditions. Co-founder and Chief Scientific Officer João Paulo Cunha said the funding gets its algorithms “into everyday wearable devices.” Investegate
The grant is tiny compared to Frontier’s market cap. A 32.9% stake works out to around €104,500, but all the cash goes to InSignals, not Frontier. The takeaway for the market isn’t the grant itself—it’s that investors get a new funding signal for a portfolio Frontier last valued at £33.5 million. The company had £1.6 million cash and posted a £3.1 million pre-tax loss for the first half.
Frontier raised new equity after warning in June it didn’t have enough cash for 12 months of operating costs without realisations. The company said if shareholders approve the conditional part, the fundraising will cover at least 12 months of expenses from Second Admission even if there are no realisations.
| Price and forecast check | Figure | Reuters calculation |
|---|---|---|
| Monday bid/offer | 15.5p/16.5p | Mid comes out to roughly 16p |
| FTSE AIM All-Share move | +0.17% | FIPP outperformed the index by about 17 percentage points using AJ Bell’s change data |
| One-analyst 12-month target | 41p | That target is about 156% over the 16p mid |
| Latest reported NAV/share | 52.7p at Dec. 31 | At 16p, the shares trade about 70% under that NAV |
| Market cap vs equity portfolio value | £13.62 mln vs £33.5 mln | Market cap stands at around 41% of carrying value for the portfolio |
Frontier’s June deal put a lid on the numbers. The offer, subscription and retail placing were all set at 12p. In total, 75.64 million existing shares and 36.67 million new shares were listed, with the count rising to 112.30 million after Second Admission if all conditions are met. Estimated maximum net proceeds were £4.0 million.
| Funding and dilution forecast | Company figure | Read-through |
|---|---|---|
| Ordinary shares on issue before the raise | 75.64 mln | Starting point for dilution |
| New shares issued | 36.67 mln | Works out to 48.476% of current share count |
| Total shares after Second Admission | 112.30 mln | New shares will make up 32.6% of total |
| Max net funds to company | £4.0 mln | Company expects this to cover at least a year of expenses from Second Admission |
| Estimated pro-forma NAV per share | About 39p | End-Dec. NAV plus £4.4 mln gross, before any costs or further changes |
Retail investors put in more orders than there were shares on offer, and current shareholders only got around 72% of their soft pre-emption rights in areas where requests hit or surpassed the set limits. The total fundraising brought in £4.4 million, subject to shareholder sign-off.
July 15 comes back into play. The general meeting is set for 9:30 a.m. London time. If resolutions are approved, Second Admission is on track for 8:00 a.m. July 16.
